Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Helsinn Therapeutics (US) Inc.

Division of Helsinn Group
www.helsinn.com

Latest From Helsinn Therapeutics (US) Inc.

New CEO of Renamed Spin-Out Fortovia Therapeutics Will Be ‘Solely US-Focused’

Newly installed Fortovia Therapeutics CEO Peter Melnyk tells Scrip his arrival and the company’s name change from Midatech Pharma US signals a strategic revamp for the privately held spin-out.

Commercial Companies

Deal Watch: Opportunity Knocks For Partnerships In Asia

ApolloBio signs on to take Inovio's HPV immunotherapy into China and Senju and Fosun sign China partnerships – all part of a wave of Chinese companies looking to bring innovative new medicines to the Greater China markets. Meanwhile, GSK signs on with Indian CRO Syngene.

Deals Business Strategies

Appointments: Changes at SOTIO, Helsinn, Sobi, AMRI, Blade and Vertex

The latest biopharma industry appointments include a new chairman at Bone Therapeutics, chief executives at SOTIO and Helsinn Therapeutics, new CFOs at Sobi, AMRI and at Blade Therapeutics, and a new CMO at Vertex Pharmaceuticals.

Appointments Companies

Appointments: Impax, Mylan, Eisai, Cipher, Hutchison and Arena Pharmaceuticals, Bridge Medicines and ProMIS

This week's round up of recent appointments includes new CEOs at Impax Laboratories, Cipher Pharmaceuticals and Bridge Medicines, and other senior appointments at Mylan, Eisai and Arena Pharmaceuticals.

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Metabolic Disorders
  • Alias(es)
  • Rejuvenon Corp.
  • Sapphire Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Helsinn Group
  • Senior Management
  • William Mann, CEO
  • Contact Info
  • Helsinn Therapeutics (US) Inc.
    Phone: (732) 603-2800
    170 Wood Ave. South
    5th Fl.
    Iselin, NJ 08830
    USA
UsernamePublicRestriction

Register